Gabriele Simonini

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 247 publications

Hepatic Involvement in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: Clinical and Therapeutic Insights From 2 Cases.

Hepatic Involvement in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: Clinical and Therapeutic Insights From 2 Cases.

Journal: The Journal of rheumatology

Published: July 15, 2026

Domains and outcome measures for the assessment of digital vasculopathy and Raynaud's phenomenon in adult and juvenile systemic sclerosis: a scoping literature review.

Domains and outcome measures for the assessment of digital vasculopathy and Raynaud's phenomenon in adult and juvenile systemic sclerosis: a scoping literature review.

Journal: Clinical and experimental rheumatology

Published: June 30, 2026

What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

Journal: Expert review of clinical immunology

Published: May 05, 2026

When adalimumab fails in childhood chronic uveitis: what comes next?

When adalimumab fails in childhood chronic uveitis: what comes next?

Journal: Expert opinion on biological therapy

Published: March 06, 2026

Diagnosis, treatment and monitoring of pediatric Behçet's disease: Systematic literature review informing the ISSAID/PRES recommendations.

Diagnosis, treatment and monitoring of pediatric Behçet's disease: Systematic literature review informing the ISSAID/PRES recommendations.

Journal: Autoimmunity reviews

Published: February 07, 2026

Recurrent pericarditis in children: Clinical and therapeutic differences from adults.

Recurrent pericarditis in children: Clinical and therapeutic differences from adults.

Journal: International journal of cardiology

Published: February 07, 2026

Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures.

Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures.

Journal: Pediatric rheumatology online journal

Published: December 16, 2025

Sirolimus to treat chronic uveitis in PTEN hamartoma tumor syndrome: experience of a target therapy customized on specific disease pathway.

Sirolimus to treat chronic uveitis in PTEN hamartoma tumor syndrome: experience of a target therapy customized on specific disease pathway.

Journal: Rheumatology (Oxford, England)

Published: December 08, 2025

Eculizumab as an adjunctive rescue treatment for life-threatening childhood onset of systemic lupus erythematosus.

Eculizumab as an adjunctive rescue treatment for life-threatening childhood onset of systemic lupus erythematosus.

Journal: Lupus

Published: November 25, 2025

Validation of Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Measures for Children With Chronic Nonbacterial Osteomyelitis.

Validation of Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Measures for Children With Chronic Nonbacterial Osteomyelitis.

Journal: Arthritis care & research

Published: November 20, 2025

Comment on: How early is early for JIA? Insights from the infantile-onset juvenile idiopathic arthritis patients of the PERA research group cohort.

Comment on: How early is early for JIA? Insights from the infantile-onset juvenile idiopathic arthritis patients of the PERA research group cohort.

Journal: Rheumatology (Oxford, England)

Published: November 10, 2025

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First-Line Therapy.

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First-Line Therapy.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 20, 2025

Showing 1-12 of 247

Last Updated: 09/26/2026